Obesity is a huge and increasing medical problem, with inadequate therapeutic options. One approach to the treatment of obesity is long-term pharmacotherapy. One modestly effective drug, orlistat, has been marketed in the United States since 1999. More recently four other drugs have been approved by the FDA: lorcaserin and Qsymia (a combination of phentermine and topiramate) in 2012 and Contrave (a combination of buproprion and naltrexone) and liraglutide (high dose) in 2014. The limited efficacy of single agents has led to the idea that additional agents and combination therapy are required. Progress in FY2017 includes the following: We wrote an editorial highlighting a remarkable study showing that treatment of patients with genetic deficiency of POMC (proopiomelanocortin) had their massive obesity revered by treatment with a melanocortin agonist, setmelanotide 1. We also wrote a commentary on a series of papers that individually appear well-done and convincing, yet fundamentally disagree. One group reported that interleukin-4 (IL-4) does not increase adipose thermogenesis and that activated macrophages do not synthesize catecholamines. This contrasts with prior findings that IL-4 activation of macrophages has been proposed to have a pivotal role in cold-induced thermogenesis by stimulating macrophage catecholamine production to recruit thermogenic beige or brite fat 2. We contributed to a study (in press) that examined the effect of a drug, JD5037, that is peripheral-acting (not acting in the brain) blocker of the endocannabinoid/CB1 receptor. The results demonstrated that peripheral CB1R blockade in diet-induced obese mice restored sensitivity to endogenous leptin. Thus, the leptin as able to elicit hypophagia via the activation of melanocortin signaling in the arcuate nucleus of the hypothalamus.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2017
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
Zip Code
Reitman, Marc L (2018) Of mice and men - environmental temperature, body temperature, and treatment of obesity. FEBS Lett 592:2098-2107
Jain, Shalini; Panyutin, Anna; Liu, Naili et al. (2018) Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors. Am J Physiol Endocrinol Metab 315:E357-E366
Xiao, Cuiying; Piñol, Ramón A; Carlin, Jesse Lea et al. (2017) Bombesin-like receptor 3 (Brs3) expression in glutamatergic, but not GABAergic, neurons is required for regulation of energy metabolism. Mol Metab 6:1540-1550
Reitman, Marc L (2017) How Does Fat Transition from White to Beige? Cell Metab 26:14-16
Reitman, Marc L (2016) Hormone-Replacement Therapy for Melanocyte-Stimulating Hormone Deficiency. N Engl J Med 375:278-9
Hall, Kevin D; Chen, Kong Y; Guo, Juen et al. (2016) Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr 104:324-33
Lateef, Dalya M; Xiao, Cuiying; Reitman, Marc L (2015) Search for an Endogenous Bombesin-Like Receptor 3 (BRS-3) Ligand Using Parabiotic Mice. PLoS One 10:e0142637
Xiao, Cuiying; Goldgof, Margalit; Gavrilova, Oksana et al. (2015) Anti-obesity and metabolic efficacy of the ?3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C. Obesity (Silver Spring) 23:1450-9
Chen, Kong Y; Muniyappa, Ranganath; Abel, Brent S et al. (2015) RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab 100:1639-45
Abreu-Vieira, Gustavo; Xiao, Cuiying; Gavrilova, Oksana et al. (2015) Integration of body temperature into the analysis of energy expenditure in the mouse. Mol Metab 4:461-70

Showing the most recent 10 out of 26 publications